These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36555568)

  • 21. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
    Boulay D; Bergis O; Avenet P; Griebel G
    Neuropsychopharmacology; 2010 Jan; 35(2):416-27. PubMed ID: 19759529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug.
    Xu Y; Zhu X; Wang H; Sun S; Yue X; Tian J
    Sci Rep; 2018 May; 8(1):6892. PubMed ID: 29720711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of MK-801-induced heat shock protein 72/73 in rat brain by antipsychotic and monoaminergic agents targeting D2, 5-HT1A, 5-HT2A and α1-adrenergic receptors.
    Romón T; Planas AM; Adell A
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):104-11. PubMed ID: 24040788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
    Black MD; Stevens RJ; Rogacki N; Featherstone RE; Senyah Y; Giardino O; Borowsky B; Stemmelin J; Cohen C; Pichat P; Arad M; Barak S; De Levie A; Weiner I; Griebel G; Varty GB
    Psychopharmacology (Berl); 2011 May; 215(1):149-63. PubMed ID: 21181124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556.
    Colodete DAE; Silva NR; Pedrazzi JFC; Fogaça MV; Cortez I; Del-Bel EA; Breuer A; Mechoulam R; Gomes FV; Guimarães FS
    Behav Pharmacol; 2023 Jun; 34(4):213-224. PubMed ID: 37171460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone.
    Fontenla JA; Osuna J; Rosa E; Castro ME; G-Ferreiro T; Loza-García I; Calleja JM; Sanz F; Rodríguez J; Raviña E
    J Med Chem; 1994 Aug; 37(16):2564-73. PubMed ID: 7914540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone.
    Horisawa T; Nishikawa H; Toma S; Ikeda A; Horiguchi M; Ono M; Ishiyama T; Taiji M
    Behav Brain Res; 2013 May; 244():66-9. PubMed ID: 23376699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
    Czopek A; Kołaczkowski M; Bucki A; Byrtus H; Pawłowski M; Kazek G; Bojarski AJ; Piaskowska A; Kalinowska-Tłuścik J; Partyka A; Wesołowska A
    Bioorg Med Chem; 2015 Jul; 23(13):3436-47. PubMed ID: 25936259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
    Zemba Cilic A; Zemba M; Cilic M; Balenovic I; Strbe S; Ilic S; Vukojevic J; Zoricic Z; Filipcic I; Kokot A; Drmic D; Blagaic AB; Tvrdeic A; Seiwerth S; Sikiric P
    Behav Brain Res; 2021 Jan; 396():112919. PubMed ID: 32956773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of presynaptic 5-HT
    Mombereau C; Arnt J; Mørk A
    Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential antipsychotic action of the selective agonist of adenosine A1 receptors, 5'-Cl-5'-deoxy-ENBA, in amphetamine and MK-801 rat models.
    Ossowska K; Kosmowska B; Wardas J
    Pharmacol Rep; 2020 Jun; 72(3):580-588. PubMed ID: 32219695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents - Design, synthesis, structural studies and pharmacological profiling.
    Stępnicki P; Targowska-Duda KM; Martínez AL; Zięba A; Wronikowska-Denysiuk O; Wróbel MZ; Bartyzel A; Trzpil A; Wróbel TM; Chodkowski A; Mirecka K; Karcz T; Szczepańska K; Loza MI; Budzyńska B; Turło J; Handzlik J; Fornal E; Poleszak E; Castro M; Kaczor AA
    Eur J Med Chem; 2023 Apr; 252():115285. PubMed ID: 37027998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.
    Oliveras I; Sánchez-González A; Sampedro-Viana D; Piludu MA; Río-Alamos C; Giorgi O; Corda MG; Aznar S; González-Maeso J; Gerbolés C; Blázquez G; Cañete T; Tobeña A; Fernández-Teruel A
    Psychopharmacology (Berl); 2017 Mar; 234(6):957-975. PubMed ID: 28154892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
    Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
    J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.
    Xu M; Wang Y; Yang F; Wu C; Wang Z; Ye B; Jiang X; Zhao Q; Li J; Liu Y; Zhang J; Tian G; He Y; Shen J; Jiang H
    Eur J Med Chem; 2018 Feb; 145():74-85. PubMed ID: 29324345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.